Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus HYDELTRASOL.
DECADRON W/ XYLOCAINE vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Corticosteroid